Patents by Inventor Wojciech J. Ardelt

Wojciech J. Ardelt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceuticals and method for making them
    Patent number: 5728805
    Abstract: Rana pipiens eggs are subjected to mechanical processing in the presence of a weakly acidic buffer to produce an extract. The extract is subjected to ion-exchange chromatography and size-exclusion chromatography. Two pharmaceuticals resulting from these steps have activity against certain cancer cells. The amino acid sequences and compositions of two preferred embodiments are disclosed.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 17, 1998
    Assignee: Alfacell Corp.
    Inventor: Wojciech J. Ardelt
  • Compositions comprising ONCONASE (tm) and lovastatin
    Patent number: 5595734
    Abstract: A pharmaceutical known by the trademark ONCONASE, as described in pending commonly owned application application number 07/436,141 filed Nov. 13, 1989, is combined with two forms of another drug known as Lovastatin. The combination of ONCONASE with Lovastatin has unexpected bioactivity in vitro against ASPC-1 human pancreatic adenocarcinoma cells, A-549 human lung carcinoma cells and HT-520 human squamous cell lung carcinoma cells.
    Type: Grant
    Filed: July 28, 1992
    Date of Patent: January 21, 1997
    Assignee: Alfacell Corporation
    Inventors: Stanislaw M. Mikulski, Wojciech J. Ardelt
  • Frog embryo and egg-derived tumor cell anti-proliferation protein
    Patent number: 5559212
    Abstract: Rana pipiens eggs are subjected to fertilization and the embryos are grown to a predetermined stage of development. The embryos and unfertilized eggs are then subjected to mechanical processing in the presence of a weakly acidic buffer to produce an extract. The extract is subjected to ion-exchange chromatography and size-exclusion chromatography.The resulting pharmaceutical has activity against certain cancer cells. The amino acid sequence and composition of the pharmaceutical are disclosed.
    Type: Grant
    Filed: August 1, 1994
    Date of Patent: September 24, 1996
    Assignee: Alfacell Corporation
    Inventor: Wojciech J. Ardelt
  • Compositions comprising ONCONASE (TM) and STELAZINE (TM) or TAMOXIFEN (TM)
    Patent number: 5540925
    Abstract: A pharmaceutical to be sold under the ONCONASE trademark, as described in pending commonly owned application application Ser. No. 07/436,141 filed Nov. 13, 1989 is combined with other drugs sold under the trademarks TAMOXIFEN and STELAZINE. The combination of ONCONASE with TAMOXIFEN has unexpected bioactivity in vitro against ASPC-1 human pancreatic adenocarcinoma cells and the combination of ONCONASE with STELAZINE has unexpected bioactivity in vitro against A-549 human lung carcinoma cells.
    Type: Grant
    Filed: August 1, 1994
    Date of Patent: July 30, 1996
    Assignee: Alfacell Corporation
    Inventors: Stanislaw M. Mikulski, Wojciech J. Ardelt
  • Compositions comprising ONCONASE(.TM.) and cisplatin, melphalan, or doxorubicin HCl
    Patent number: 5529775
    Abstract: A pharmaceutical known by the trademark ONCONASE, as described in pending commonly owned application application Ser. No. 07/436,141 filed Nov. 13, 1989, is combined with drugs sold under the names cisplatin, Melphalan and Doxorubicin HCl. The combinations of ONCONASE with these drugs has unexpected bioactivity in vitro against OVCAR-3 human ovarian adenocarcinoma cells.
    Type: Grant
    Filed: August 1, 1994
    Date of Patent: June 25, 1996
    Assignee: Alfacell Corporation
    Inventors: Stanislaw M. Mikulski, Wojciech J. Ardelt
  • Pharmaceutical for treating tumors and method for making it
    Patent number: 4882421
    Abstract: Rana pipiens eggs are subjected to fertilization and the embryos are grown to a predetermined stage of development. The embryos and unfertilized eggs are then subjected to mechanical processing in the presence of a weakly acidic buffer to produce an extract. The extract is subjected to ion-exchange chromatography and size-exclusion chromatography.The resulting pharmaceutical has activity against certain cancer cells. A partial amino acid sequence of the pharmaceutical is disclosed.
    Type: Grant
    Filed: April 6, 1988
    Date of Patent: November 21, 1989
    Assignee: Alfacell Corporation
    Inventors: Kuslima Shogen, Stanislaw M. Mikulski, Wojciech J. Ardelt